Ocrevus

Active Ingredient(s): Ocrelizumab
FDA Approved: * March 28, 2017
Pharm Company: * GENENTECH INC
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ocrevus Overview

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate.[1] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[1] It was approved by the FDA in March 2017 as a treatment for multiple sclerosis, and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed by Hoffmann–La Roche's subsidiary Genentech unde...

Read more Ocrevus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ocrelizumab

Recent Ocrevus Forums: RSS Feed

Ocrevus AWP pricing
Post a Reply
I am trying to locate the AWP for Ocrevus. Any ideas? I have not been able to locate it anywhere. Thank you.
Updated 2 hours ago.
 

Possible Dosages for this and Related Drugs:

Ocrelizumab
  • Injection: 30mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ocrevus: (1 result)

Sorted by National Drug Code
  • 50242-150 Ocrevus 300 mg/10ml Intravenous Injection by Genentech, Inc.

Other drugs which contain Ocrelizumab or a similar ingredient: (1 result)


Possibly related Ocrevus Topics:

Ocrevus AWP pricing I am trying to locate the AWP for Ocrevus. Any ideas? I have not been able to locate it anywhere. Thank you....